


AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

1-76 (cancelled).


77 (new). A method of treatment of a condition associated with raised activity of the enzyme core 2 GlcNAc-T comprising administration of an effective amount of a compound of the formula I to a patient in need thereof;




wherein R₁ is -OH, C₁₋₆ alkoxy, -NR₈R₉, or a monosaccharide of the formula IIa;



R₂ is -OH, C₁₋₆ alkoxy or a monosaccharide of the formula IIb:



R₃ is -OH, C₁₋₆ alkoxy or a monosaccharide of the formula IIc;



R₄ is C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl or C₁₋₆-alkoxy-C₁₋₆-alkyl;

R₅ is C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl or C₁₋₆ alkoxy-C₁₋₆-alkyl;

R₆ is C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl or C₁₋₆-alkoxy-C₁₋₆-alkyl;

R₇ is C₂₋₆ alkyl, C₁₋₆ hydroxyalkyl or C₁₋₆-alkoxy-C₁₋₆-alkyl;

R₈ is H, C₁₋₆ alkyl or C₁₋₆ acyl;

R₉ is H, C₁₋₆ alkyl or C₁₋₆ acyl; and

Z is a steroid group;

or a pharmaceutically acceptable salt, ester or tautomeric form or derivative thereof.

78 (new). A method of treatment as described in claim 77 in which R₁ is a monosaccharide of the formula IIa.

79 (new). A method of treatment as described in claim 78 in which R₅ is C₁₋₆ alkyl or C₁₋₆ hydroxyalkyl.

80 (new). A method of treatment as described in claim 78 in which R₅ is —CH₃, —C₂H₅, —CH₂OH or —C₂H₄OH.


81 (new). A method of treatment as described in claim 77 in which R_3 is a monosaccharide of the formula IIc.

82 (new). A method of treatment as described in claim 81 in which R_7 is C_{1-6} hydroxyalkyl or C_{1-6} -alkoxy- C_{1-6} -alkyl.

83 (new). A method of treatment as described in claim 81 in which R_7 is $-CH_2OH$ or C_{1-6} alkoxyethyl.

84 (new). A method of treatment as described in claim 81 in which R_7 is $-CH_2OH$.

85 (new). A method of treatment as described in claim 77 in which the compound of the formula I is a compound of the formula III:



wherein:

R₄ is C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl or C₁₋₆-alkoxy-C₁₋₆-alkyl;

R₅ is C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl or C₁₋₆-alkoxy-C₁₋₆-alkyl; and

R₇ is C₂₋₆ alkyl, C₁₋₆ hydroxyalkyl or C₁₋₆-alkoxy-C₁₋₆-alkyl.

86 (new). A method of treatment as described in claim 85 in which R₄ is C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl.

87 (new). A method of treatment as described in claim 85 in which R₄ is -CH₂OH or -CH₃.

88 (new). A method of treatment as described in claim 85 in which R₅ is C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl.

89 (new). A method of treatment as described in claim 85 in which R₅ is -CH₃, -C₂H₅, -CH₂OH or -C₂H₄OH.

90 (new). A method of treatment as described in claim 85 in which R₇ is C₁₋₆ hydroxyalkyl or C₁₋₆-alkoxy-C₁₋₆-alkyl.

91 (new). A method of treatment as described in claim 85 in which R₇ is -CH₂OH or C₁₋₆ alkoxymethyl.

92 (new). A method of treatment as described in claim 85 in which R_7 is $-\text{CH}_2\text{OH}$.

93 (new). A method as described in claim 85 wherein compounds of the formula III are compounds of the formula I wherein:


R_1 is rhamnose;

R_2 is $-\text{OH}$;


R_3 is glucose; and

R_4 is CH_2OH .

94 (new). A method as described in claim 85 wherein compounds of the formula III are compounds of the formula IV



95 (new). A method as described in claim 77 in which the compound of the formula I is a compound of the formula V:



wherein:

R_1 is OH, C_{1-6} alkoxy or NR_8R_9 , or a monosaccharide of the formula IIa:

R_4 is C_{1-6} alkyl, C_{1-6} hydroxyalkyl or C_{1-6} -alkoxy- C_{1-6} -alkyl;

R_5 is C_{1-6} alkyl, C_{1-6} hydroxyalkyl or C_{1-6} -alkoxy- C_{1-6} alkyl;

R_6 is C_{1-6} alkyl, C_{1-6} hydroxyalkyl or C_{1-6} -alkoxy- C_{1-6} -alkyl;

R_8 is H, C_{1-6} alkyl or C_{1-6} acyl;

R_9 is H, C_{1-6} alkyl or C_{1-6} acyl; and

Z is a steroid group.

96 (new). A method as described in claim 95 in which R_1 is OH, or NR_8R_9 .

97 (new). A method as described in claim 95 in which R_1 is NR_8R_9 ;

R_8 is H, C_{1-6} alkyl or C_{1-6} acyl; and

R_9 is H, C_{1-6} alkyl or C_{1-6} acyl.

98 (new). A method as described in claim 95 in which R_1 is NR_8R_9 ;

R_8 is H; and

R_9 is H, C_{1-6} alkyl or C_{1-6} acyl.

99 (new). A method as described in claim 95 in which R_1 is NR_8R_9

R_8 is H; and

R_9 is C_{1-6} acyl.


100 (new). A method as described in claim 95 in which R_1 is NR_8R_9 ;

R_8 is H; and

R_9 is $-COCH_3$.

101 (new). A method as described in claim 95 in which the compound of formula IV is $Gal\beta 1 \rightarrow 3(6\text{-deoxy})GalNAc\alpha\text{-Z}$.

102 (new). A method according to claim 77 in which the steroid group is a group of the formula VII:



VII

wherein:

R₁₂ is H, -OH, C₁₋₆ alkyl or C₁₋₆ alkoxy;

R₁₃ is H, -OH, =O, or C₁₋₆ alkyl;

R₁₄ is H, -OH or C₁₋₆ alkyl or R₁₄ and R₃₃ taken together represent the second bond of a double bond joining adjacent carbon atoms;

R₁₅ is H, or -OH, or R₁₅ and R₃₃ taken together are =O;

R₁₆ is H, -OH or =O;


R₁₇ is H, -OH or =O;

R₁₈ is H, -OH, C₁₋₆ alkoxy or C₁₋₆ alkyl;

R₁₉ is H, -OH, C₁₋₆ alkyl or C₁₋₆ alkoxy;

R₂₀ is H, -OH, C₁₋₆ alkoxy or C₁₋₆ alkyl;

R₂₁ is H, -OH, C₁₋₆ alkyl, C₁₋₆ alkoxy or is a group of the formula VIII:



R₂₂ is H, -OH, C₁₋₆ alkyl or C₁₋₆ alkoxy;

R₂₃ is H, -OH, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, C₁₋₆-alkoxy-C₁₋₆-alkyl, =CH₂ or =CH-C₁₋₆-alkyl;

R₂₄ is H, C₁₋₆ alkyl, C₁₋₆ acyl or a monosaccharide MS;

R₂₈ and R₂₉ are the same or different and are H or -OH;

R₃₂ is H, -OH or =O;

R₃₃ is H, or R₃₃ and R₁₅ taken together are =O, or R₃₃ and R₁₄ taken together represent the second bond of a double bond joining adjacent carbon atoms; MS is

selected from a group consisting of rabinose, xylose, lyxose, ribose, glucose, mannose, galactose, allose, altrose, gulose, idose, talose, ribulose, xylulose, fructose, sorbose, tagatose, psicose, sedoheptulose, deoxyribose, fucose, rhamnose, 2-deoxy-glucose, quinovose, abequose, glucosamine, mannosamine, galactosamine, neuraminic acid, muramic acid, N-acetyl-glucosamine, N-acetyl-mannosamine, N-acetyl-galactosamine, N-acetylneuraminic acid, N-acetylmuramic acid, O-acetylneuraminic acid, N-glycolylneuraminic acid, fructuronic acid, tagaturonic acid, glucuronic acid, mannuronic acid, galacturonic acid, iduronic acid, sialic acid and guluronic acid; and

Y is N or O.

103 (new). A method according to claim 102 in which Y is O.

104 (new). A method according to claim 102 in which R_{21} is a group of the formula VIII.

105 (new). A method according to claim 104 in which R_{24} is C_{1-6} alkyl, C_{1-6} acyl or a monosaccharide MS.

106 (new). A method according to claim 104 in which R_{24} is C_{1-6} acyl or a monosaccharide MS.

107 (new). A method according to claim 104 in which R_{24} is a monosaccharide MS.

108 (new). A method according to claim 105, in which MS is selected from the group consisting of glucose, galactose, mannose, fucose, N-acetyl-glucosamine, N-acetyl-galactosamine and sialic acid.

109 (new). A method according to claim 105, in which MS is glucose.

110 (new). A method according to claim 104 in which R_{23} is C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} -alkoxy- C_{1-6} -alkyl, $=CH_2$ or $=CH-C_{1-6}$ -alkyl.

111 (new). A method according to claim 104 in which R_{23} is C_{1-6} alkyl, C_{1-6} hydroxyalkyl or $=CH_2$.

112 (new). A method according to claim 104 in which R_{23} is $-C_2H_4OH$, $-CH_2OH$, C_{1-6} alkyl, or $=CH_2$.

113 (new). A method according to claim 104 in which R_{23} is $-C_2H_4OH$, $-CH_2OH$, $-C_2H_5$, $-CH_3$ or $=CH_2$.

114 (new). A method according to claim 104 in which R_{23} is $-CH_3$.

115 (new). A method according to claim 104 in which R_{23} is $=CH_2$.

116 (new). A method of claim 104 in which R₂₂ is H, -OH, or C₁₋₆ alkoxy.

117 (new). A method of claim 104 in which R₂₂ is H.

118 (new). A method of claim 102 in which R₁₉ is H, -OH, or C₁₋₆ alkyl.

119 (new). A method of claim 102 in which:

R₁₂ is H, -OH

R₁₃ is H or -OH;

R₁₄ is H, or -OH or R₁₄ and R₃₃ taken together represent the second bond of a double bond joining adjacent carbon atoms;

R₁₅ is H, or R₁₅ and R₃₃ taken together are =O;

R₁₈ is H, -OH or C₁₋₆ alkoxy;

R₁₉ is C₁₋₆ alkyl;

R₂₀ is H, -OH or C₁₋₆ alkoxy;

R₃₂ is H, -OH or =O; and

R₃₃ is H, or R₃₃ and R₁₅ taken together are =O, or R₃₃ and R₁₄ taken together represent the second bond of a double bond joining adjacent carbon atoms.

120 (new). A method of claim 102 in which:


R₁₆ is H or =O;

R₁₇ is H or -OH;

R₁₈ is H or -OH; and

R_{20} is -OH or C_{1-6} alkoxy.

121 (new). A method of claim 102 in which the steroid group is selected from a group consisting of:



wherein:

R_{18} is H or -OH;

R_{20} is -OH or C_{1-6} alkoxy;

R_{24} is glucose or C_{1-6} acyl; and


R_{29} is H or -OH.

122 (new). A method of claim 77 in which the compound of the formula I is selected from the group consisting of
trigoneoside IVa which is (3 β ,25S)-26-(β -D-glucopyranosyloxy)-22-hydroxyfurost-

5-en-3-yl-O- α -L-rhamnopyranosyl-(1 \rightarrow 2)-O-

[β -D-glucopyranosyl-(1 \rightarrow 4)]- β -D-glucopyranoside, glycoside F which is (3 β)-26-(β -D-glucopyranosyloxy)-22-hydroxyfurost-5-en-3-yl-O- α -L-rhamnopyranosyl-(1 \rightarrow 2)-O-[β -D-glucopyranosyl-(1 \rightarrow 4)]- β -D-glucopyranoside, shatavarin I, compound 3, pardarinnoside C.

123 (new). A method according to claim 77 in which the steroid group is a group of the formula VIII:



wherein:

R₁₂ is H, -OH, C₁₋₆ alkyl or C₁₋₆ alkoxy;

R₁₃ is H, -OH, =O, or C₁₋₆ alkyl;

R₁₄ is H, -OH or C₁₋₆ alkyl or R₁₄ and R₃₃ taken together represent the second bond of a double bond joining adjacent carbon atoms;

R₁₅ is H, or -OH, or R₁₅ and R₃₃ taken together are =O;

R₁₆ is H, -OH or =O;

R₁₇ is H, -OH or =O;

R₁₈ is H, -OH, C₁₋₆ alkoxy or C₁₋₆ alkyl;

R₁₉ is H, -OH, C₁₋₆ alkyl or C₁₋₆ alkoxy;

R₂₀ is H, -OH, C₁₋₆ alkoxy or C₁₋₆ alkyl;

R₂₇ is H, -OH, C₁₋₆ alkyl, C₁₋₆ alkoxy or C₁₋₆ hydroxyalkyl;

R₂₈ and R₂₉ are the same or different and are H or -OH;

R₃₂ is H, -OH or =O; and

R₃₃ is H, or R₃₃ and R₁₅ taken together are =O, or R₃₃ and R₁₄ taken together represent the second bond of a double bond joining adjacent carbon atoms.

124 (new). A method of claim 123 in which R₂₇ is H, C₁₋₆ alkyl, or C₁₋₆ alkoxy.

125 (new). A method of claim 123 in which R₂₇ is H, or C₁₋₆ alkyl.

126 (new). A method of claim 123 in which R₁₉ is H, -OH, or C₁₋₆ alkyl.

127 (new). A method of claim 123 in which R₂₀ is —OH or C₁₋₆ alkoxy.

128 (new). A method of claim 123 in which

R₁₂ is H or -OH

R₁₃ is H or -OH;

R₁₄ is H, or -OH or R₁₄ and R₃₃ taken together represent the second bond of a double bond joining adjacent carbon atoms;

R₁₅ is H, or R₁₅ and R₃₃ taken together are =O;

R₁₆ is H, -OH or =O;

R₁₇ is H, -OH or =O;


R₁₈ is H, -OH or C₁₋₆ alkoxy

R₁₉ is C₁₋₆ alkyl;


R₃₂ is H, -OH or =O; and

R₃₃ is H, or R₃₃ and R₁₅ taken together are =O, or R₃₃ and R₁₄ taken together represent the second bond of a double bond joining adjacent carbon atoms.


129 (new). A method of claim 123 in which the compound of the steroid group is a compound of the formula IXa



130 (new). A method of claim 123 in which the compound of the formula I is a compound of the formula:



131 (new). A method of claim 77 in which the steroid group is of the formula XI:



XI

wherein:

R₁₂ is H, -OH, C₁₋₆ alkyl or C₁₋₆ alkoxy;

R₁₃ is H, -OH, =O, or C₁₋₆ alkyl;

R₁₄ is H, -OH or C₁₋₆ alkyl or R₁₄ and R₃₃ taken together represent the second bond of a double bond joining adjacent carbon atoms;

R₁₅ is H, or -OH, or R₁₅ and R₃₃ taken together are =O;

R₁₆ is H, -OH or =O;

R₁₇ is H, -OH or =O;

R₁₈ is H, -OH, C₁₋₆ alkoxy or C₁₋₆ alkyl;

R₁₉ is H, -OH, C₁₋₆ alkyl or C₁₋₆ alkoxy;

R₂₅ is H, -OH, C₁₋₆ alkyl or C₁₋₆ alkoxy;

R₂₆ is H, -OH, C₁₋₆ alkyl, C₁₋₆ hydroxyalkyl, C₁₋₆-alkoxy-C₁₋₆-alkyl, =CH₂ or =CH-C₁₋₆-alkyl;

R_{28} and R_{29} are the same or different and are H or -OH;

R_{31} is H or -OH;

R_{32} is H, -OH or =O;

R_{33} is H, or R_{33} and R_{15} taken together are =O, or R_{33} and R_{14} taken together represent the second bond of a double bond joining adjacent carbon atoms;

R_{34} is H or -OH; and

X is O, S or NH.

132 (new). A method of claim 131 in which X is O or NH;

133 (new). A method of claim 131 in which X is O;

134 (new). A method of claim 131 wherein R_{26} is C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-6} -alkoxy- C_{1-6} -alkyl, =CH₂ or =CH- C_{1-6} -alkyl.

135 (new). A method of claim 131 wherein R_{26} is C_{1-6} alkyl, C_{1-6} hydroxyalkyl or =CH₂.

136 (new). A method of claim 131 wherein R_{26} is -C₂H₄OH, -CH₂OH, C_{1-6} alkyl, or =CH₂.

137 (new). A method of claim 131 wherein R_{26} is -C₂H₄OH, -CH₂OH, -C₂H₅, -CH₃ or =CH₂.

138 (new). A method of claim 131 wherein R_{26} is $-CH_3$ or $=CH_2$.

139 (new). A method of claim 131 wherein R_{19} is H, -OH, C_{1-6} alkyl.

140 (new). A method of claim 131 wherein R_{19} is C_{1-6} alkyl.

141 (new). A method of claim 131 wherein:

R_{12} is H, or -OH;

R_{13} is H, or -OH;

R_{14} is H or R_{14} and R_{33} taken together represent the second bond of a double bond joining adjacent carbon atoms;

R_{15} is H, or R_{15} and R_{33} taken together are $=O$;

R_{18} is H or -OH;

R_{25} is H or -OH;

R_{28} and R_{29} are H;

R_{31} is H or -OH;

R_{33} is H, or R_{33} and R_{15} taken together are $=O$, or R_{33} and R_{14} taken together represent the second bond of a double bond joining adjacent carbon atoms; and

R_{34} is H or -OH.

142 (new). A method of claim 131 wherein:

R_{15} is H;







R_{16} is H or -OH;

R_{17} is H or -OH;

R_{32} is H or -OH; and

R_{33} is H, or R_{33} and R_{14} taken together represent the second bond of a double bond joining adjacent carbon atoms.

143 (new). A method of claim 131 in which the steroid group of the formula XI is selected from the group consisting of:



144 (new). A method of claim 131 in which the steroid group of the formula XI is selected from the group consisting of diosgenin, yamogenin, tigogenin, neotigogenin, sarsasapogenin, smilagenin, hecogenin, solasodine or tomatidine.

145 (new). A method of claim 77 in which the compounds of the formula I are selected from the group consisting of:

Shatavarin IV which is sarsasapogenin 3-O- α -L-rhamnopyranosyl-(1 \rightarrow 2)-O-[β -D-glucopyranosyl-(1 \rightarrow 4)]- β -D-glucopyranoside,

Compound 12 which is solasodine 3-O- α -L-rhamnopyranosyl-(1 \rightarrow 2)-O-[β -D-glucopyranosyl-(1 \rightarrow 4)]- β -D-glucopyranoside,

Deltonin which is (3 β ,25R)-spirost-5-en-3-yl-O- α -L-rhamnopyranosyl-(1 \rightarrow 2)-O-[β -D-glucopyranosyl-(1 \rightarrow 4)]- β -D-Glucopyranoside, and

Balanitin VI is (3 β ,25S)-spirost-5-en-3-yl-O- α -L-rhamnopyranosyl-(1 \rightarrow 2)-O-[β -D-glucopyranosyl-(1 \rightarrow 4)]- β -D-Glucopyranoside.

146 (new). The method of claim 77 in which the condition is an inflammatory disease, asthma, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, diabetic cardiomyopathy, myocardial dysfunction, cancer, cancer metastasis or diabetic retinopathy.

147 (new). The method of claim 77 in which the condition is leukaemia, oral cavity carcinomas, pulmonary cancers such as pulmonary adenocarcinoma, colorectal cancer, bladder carcinoma, liver tumours, stomach tumours colon tumours, prostate

cancer, testicular tumour, mammary cancer, lung tumours oral cavity carcinomas and any cancers where core 2 GlcNAc-T expression is raised above normal levels for that tissue type.


148 (new). The use of a compound disclosed in the method of claim 77 in the manufacture of a medicament for the treatment of a condition associated with raised activity of the enzyme core 2 GlcNAc-T.

149 (new). Use as described in claim 148 in which the condition is an inflammatory disease, asthma, rheumatoid arthritis, atherosclerosis inflammatory bowel disease, diabetic cardiomyopathy, myocardial dysfunction, cancer, cancer metastasis or diabetic retinopathy.

150 (new). Use as described in claim 145 in which the condition is leukaemia, oral cavity carcinomas, pulmonary cancers such as pulmonary adenocarcinoma, colorectal cancer, bladder carcinoma, liver tumours, stomach tumours colon tumours, prostate cancer, testicular tumour, mammary cancer, lung tumours oral cavity carcinomas and any cancers where core 2 GlcNAc-T expression is raised above normal levels for that tissue type.

151 (new). A pharmaceutical composition comprising a compound disclosed in the method of claim 77.

152 (new). A compound of the formula:



153 (new). Use of the compound of the formula XII as described in claim 152
in therapy.